Meprobamate is a white powder with a characteristic odor and a bitter taste. It is slightly soluble in water, freely soluble in acetone and alcohol, and sparingly soluble in ether.
Meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic.
The effectiveness of meprobamate tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.
Media Articles Related to Meprobamate
Anxiety: Speeding the Decline to Alzheimer's?
Source: Medscape Internal Medicine Headlines [2015.01.20]
In patients with mild cognitive impairment, anxiety strongly predicts onset of dementia within 3 years.
Depression, Anxiety Can Precede Memory Loss in Alzheimer's, Study Finds
Source: MedicineNet Dementia Specialty [2015.01.15]
Title: Depression, Anxiety Can Precede Memory Loss in Alzheimer's, Study Finds
Category: Health News
Created: 1/14/2015 12:00:00 AM
Last Editorial Review: 1/15/2015 12:00:00 AM
Source: MedicineNet Bipolar Disorder Specialty [2015.01.07]
Category: Symptoms and Signs
Created: 10/13/2003 12:00:00 AM
Last Editorial Review: 1/7/2015 12:00:00 AM
Pitt researchers find link exists between white matter and concussion-related depression and anxiety
Source: Anxiety / Stress News From Medical News Today [2015.01.05]
White matter brain abnormalities in some patients with depression disorders closely resemble abnormalities found in patients who have experienced a mild traumatic brain injury (mTBI), more commonly...
Holiday Depression, Anxiety, and Stress
Source: MedicineNet Gonorrhea In Women Specialty [2014.12.04]
Title: Holiday Depression, Anxiety, and Stress
Category: Diseases and Conditions
Created: 11/8/1999 12:00:00 AM
Last Editorial Review: 12/4/2014 12:00:00 AM
Published Studies Related to Meprobamate
Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. [2003.06]
Implementation of regulations to control the prescribing of benzodiazepines in New York State in 1989 resulted in a 55% decrease in benzodiazepine prescribing, with a concomitant increase in the rates of prescribing older sedative-hypnotic compounds such as butabarbital (30% increase) and meprobamate (125% increase).
Reports of Suspected Meprobamate Side Effects
Toxicity TO Various Agents (28),
Respiratory Arrest (15),
Cardiac Arrest (15),
Accidental Death (14),
Drug Abuse (11),
Completed Suicide (11),
Multiple Drug Overdose Accidental (5),
Pulmonary Congestion (5),
Pulmonary Oedema (4), more >>
Page last updated: 2015-01-20